PFE, CEO was on CMBC today at around 2:30 pm and stated they were looking at phase 2 /phase 3 biotechs not bolt on companies....
If Hikma mentioned Amarin/ Vascepa by name at the JPM conference in discussions, please forward it to Elisabeth, IR ... the amount you indicated does represent more than high trig scripts...
BB...This Hickma admission of their goals regarding Vascepa was probably submitted in their proposed lecture to the JPM meeting, well in advance before the present trial, which is now taking place...I'm really surprised they went ahead with this talk while the trial is going on...since it exposes their true infringing intentions regarding Vascepa.
I'd be interested in seeing Hickma's explanation of how what they have been saying at the JPM meeting is consistent with what they have been saying in court.